You are using an outdated browser. Please upgrade your browser to improve your experience.


Ligand Summary
Ligand Structure
Rendered image for the query structure
Delgocitinib, a janus kinase (JAK) inhibitor, is being approved for the treatment of inflammatory skin conditions. Delgocitinib inhibited the activation of inflammatory cells, such as T cells, B cells, monocytes and mast cells, in vitro and inhibited Th1-, Th2- and Th17-type cytokine production from both T cells and non-T cells.
Synonyms & Links
Guide to Pharmacology: 9619
DrugCentral: 5426

Target Activities